Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Surmodics, Inc. - Common Stock (NQ:SRDX)

28.33 +0.61 (+2.20%)
Streaming Delayed Price Updated: 2:04 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Surmodics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Surmodics to Report Third Quarter of Fiscal 2025 Financial Results on August 8
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30
From Surmodics, Inc.
Via Business Wire
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon
From Surmodics, Inc.
Via Business Wire
Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries
From Surmodics, Inc.
Via Business Wire
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
From Surmodics, Inc.
Via Business Wire
Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries
From Surmodics, Inc.
Via Business Wire
Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Surmodics, Inc.
Via Business Wire
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System
From Surmodics, Inc.
Via Business Wire
Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results
From Surmodics, Inc.
Via Business Wire
SURMODICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, SRDX, AGS, VAPO on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SRDX, ATRI on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.
From Surmodics, Inc.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Marathon Oil Corporation (NYSE – MRO), Atrion Corporation (Nasdaq – ATRI), Surmodics, Inc. (Nasdaq – SRDX), Akili, Inc. (Nasdaq – AKLI)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Marathon Oil Corporation (NYSE – MRO), Atrion Corporation (Nasdaq – ATRI), Surmodics, Inc. (Nasdaq – SRDX), Akili, Inc. (Nasdaq – AKLI)
From Brodsky & Smith LLC
Via GlobeNewswire
SRDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surmodics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
From Surmodics, Inc.
Via Business Wire
Surmodics to Participate in Upcoming Investor Conferences in March and April
From Surmodics, Inc.
Via Business Wire
Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee
From Surmodics, Inc.
Via Business Wire
Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1
From Surmodics, Inc. Surmodics, Inc.
Via Business Wire
Surmodics to Host Virtual Annual Meeting of Shareholders
From Surmodics, Inc.
Via Business Wire
Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium
From Surmodics, Inc.
Via Business Wire
Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium
From Surmodics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.